BDNF

Brain-derived neurotrophic factor (BDNF) is a neurotrophin primarily produced in the brain, particularly by neurons and astrocytes, playing a crucial role in neuronal survival, growth, and synaptic plasticity. Researchers primarily study BDNF for its involvement in cognitive functions and its implications in various neurological and psychiatric disorders. Key findings indicate that exercise can significantly increase BDNF levels, which may enhance cognitive function and mood, while lower BDNF levels are associated with conditions such as post-stroke depression and diabetes. Current research is exploring the mechanisms of BDNF in brain health and disease, with clinical evidence suggesting its potential as a target for therapeutic strategies in treating neurological disorders. Overall, BDNF remains a focal point in neuroscience, highlighting its importance in understanding brain function and pathology.

Brain-Derived Neurotrophic Factor (BDNF), also known as Abrineurin, is an endogenous protein predominantly produced in the brain. It belongs to the neurotrophin family, which is a group of growth factors involved in the development and function of the nervous system. BDNF is primarily synthesized by neurons and astrocytes, and it plays a crucial role in maintaining neuronal health and plasticity. Researchers have extensively studied BDNF due to its abundant expression in the brain and its significant impact on neuronal survival, differentiation, and synaptic plasticity. BDNF is involved in various physiological processes, including cognitive functions, mood regulation, and response to physical exercise. It has been implicated in several research areas, such as neurodegenerative diseases, psychiatric disorders, and recovery from brain injuries. BDNF exerts its effects by binding to the TrkB receptor, initiating a cascade of intracellular signaling pathways that promote neuronal survival, growth, and synaptic modulation. This signaling is crucial for processes like learning and memory. BDNF's pharmacokinetic properties are not fully characterized, but it is known to have a short half-life and is rapidly metabolized. Its bioavailability is limited when administered orally due to degradation in the gastrointestinal tract. Clinically, BDNF is not directly used as a therapeutic agent, but its role in neurological and psychiatric conditions makes it a target for research into potential treatments. Regulatory agencies have not approved BDNF as a drug, but its modulation is being explored in clinical trials for various conditions.

BDNF primarily acts on the TrkB receptor, triggering downstream signaling pathways such as the MAPK/ERK, PI3K/Akt, and PLCγ pathways. These cascades lead to enhanced neuronal survival, differentiation, and synaptic plasticity, which are vital for cognitive functions and mood regulation.

Brain-derived neurotrophic factor (BDNF) primarily exerts its effects through the activation of the tropomyosin receptor kinase B (TrkB) receptors, initiating downstream signaling pathways such as the phosphoinositide 3-kinase (PI3K)/Akt pathway and the mitogen-activated protein kinase (MAPK) pathway. These signaling cascades are crucial for promoting neuronal survival, synaptic plasticity, and neurogenesis. While the role of BDNF in neuronal function is well characterized, its complete physiological mechanisms, particularly in astrocytes and various neuropathologies, remain to be fully elucidated.

Current evidence is limited regarding the specific physiological roles of BDNF in astrocytes, particularly in different brain regions and developmental stages, necessitating further research to elucidate these mechanisms and their implications in neuropathologies. Additionally, the relationship between BDNF levels and cognitive or mood outcomes in individuals with diabetes remains ambiguous, highlighting the need for larger randomized controlled trials to assess the effects of exercise on BDNF in diabetic populations. Furthermore, the mechanisms underlying the role of BDNF in post-stroke depression are not well understood, indicating a need for studies that explore the temporal changes in BDNF levels following stroke and their correlation with depressive symptoms.